Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-11-04 |
| Court | District Court, N.D. West Virginia | Date Terminated | 2023-03-08 |
| Cause | 35:271 Patent Infringement | Assigned To | John Preston Bailey |
| Jury Demand | None | Referred To | |
| Patents | 10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-10-18 | 156 | of infringing United States Patent Nos. 7,759,328 (the "#328 patent"), 8,143,239 (the 1 …quot;#239 patent"), 8,575,137 (the "#137 patent"), and 7,967,011 (the #011 patent").…additional patent to the lawsuit, United States Patent No. 10,166,247 (the "#247 patent"). See…Pharmaceuticals Inc. ("Mylan") and 3M Company for patent infringement. Before me is Mylan's motion …Paragraph IV certifications against the asserted patents. D.I. 41, Ex. B. On August 15, 2018, the FDA sent | External link to document | |
| 2021-03-02 | 181 | Memorandum & Opinion | add infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted its…States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 of United States Patent No. …the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137 (“the ’137 Patent”) (collectively…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit… expiration of the patents-in-suit. The Drug Price Competition and Patent Term Restoration Act | External link to document |
| 2022-11-09 | 207 | Memorandum & Opinion | claims 2 and 3 of United States Patent No. 10,166,247 (“the ’247 patent”) are valid and enforceable. Following…United States Patent Nos. 7,759,328 (“the ’328 patent”); 8,143,239 (“the ’239 patent”); 8,575,137 (“…328 patent; claims 12, 13, 18, and 19 of the ’239 patent; and claims 10 and 19 of the ’137 patent (“the… ’247 patent, but does not infringe the Previously Tried Patents or claim 4 of the ’247 patent. Id. at…(“the ’137 patent”); and 7,967,011 (“the ’011 patent”) (1:19CV203, Dkt. No. 1). Thereafter, AstraZeneca | External link to document |
| 2023-03-08 | 212 | Order Dismissing Case | asserted in this action related to U.S. Patent No. 10,166,247 are DISMISSED WITH PREJUDICE; (4) Defendants…2019 8 March 2023 1:19-cv-00203 835 Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
| 2018-10-11 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,759,328; 8,143,239; 8,575,137…2019 2 March 2021 1:19-cv-00203 835 Patent - Abbreviated New Drug Applications (ANDA) | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
